Arrowhead Pharmaceuticals Inc (ARWR) concluded trading on Thursday at a closing price of $21.53, with 3.85 million shares of worth about $82.9 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -25.19% during that period and on January 23, 2025 the price saw a gain of about 9.23%. Currently the company’s common shares owned by public are about 124.38M shares, out of which, 115.84M shares are available for trading.
Stock saw a price change of 13.73% in past 5 days and over the past one month there was a price change of 10.41%. Year-to-date (YTD), ARWR shares are showing a performance of 14.52% which decreased to -35.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $17.05 but also hit the highest price of $36.72 during that period. The average intraday trading volume for Arrowhead Pharmaceuticals Inc shares is 1.53 million. The stock is currently trading 11.09% above its 20-day simple moving average (SMA20), while that difference is up 3.61% for SMA50 and it goes to -5.73% lower than SMA200.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) currently have 124.38M outstanding shares and institutions hold larger chunk of about 76.43% of that.
The stock has a current market capitalization of $2.68B and its 3Y-monthly beta is at 0.96. It has posted earnings per share of -$5.00 in the same period. It has Quick Ratio of 6.74 while making debt-to-equity ratio of 4.59. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARWR, volatility over the week remained 4.88% while standing at 5.33% over the month.
Analysts are in expectations that Arrowhead Pharmaceuticals Inc (ARWR) stock would likely to be making an EPS of -0.72 in the current quarter, while forecast for next quarter EPS is -0.7 and it is -3.98 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.43 which is 2.91 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.24 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 49.60% while it is estimated to decrease by -35.34% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on June 05, 2024 offering a Neutral rating for the stock and assigned a target price of $31 to it. Coverage by BofA Securities stated Arrowhead Pharmaceuticals Inc (ARWR) stock as a Buy in their note to investors on December 04, 2023, suggesting a price target of $29 for the stock. Stock get a Market perform rating from SVB Securities on May 12, 2023.
